Role of sumoylation in alcoholic liver disease
Role of sumoylation in alcoholic liver disease
批准号:
8566624
负责人:
Maria Lauda Tomasi
金额:
$16.16万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-30 至 2018-08-31
关键词:
AdipocytesAlcohol abuseAlcoholic HepatitisAlcoholic Liver DiseasesAnimal ModelApoptosisCell LineCell physiologyCellsCellular Stress ResponseCirrhosisCountryDNADNA RepairDNase-I FootprintingDataDevelopmentEnzymesEthanolEthanol MetabolismFatty acid glycerol estersFibrosisGenesGenetic TranscriptionGillsHalf-LifeHealthHepaticHepatic Stellate CellHepatocyteHomeostasisHumanInflammatory ResponseInfusion proceduresInjuryIntracellular TransportKupffer CellsLentivirus VectorLipidsLipopolysaccharidesLiverLiver diseasesMass Spectrum AnalysisMessenger RNAMinorModificationMolecularMusNuclearOxidative StressPathogenesisPathway interactionsPlayPost-Translational Protein ProcessingPrimary carcinoma of the liver cellsProductionProteinsRNA InterferenceReactive Oxygen SpeciesReportingRiskRoleRunningSUMO-1 ProteinSignal TransductionSiteTechniquesTechnologyTestingTriglyceridesUbiquitin-Conjugating Enzymesalcohol abuse therapybasecell typecytokinedesignfeedingfunctional outcomesin vivomacrophagemortalitynovelnovel therapeuticspreventpromoterprotein activationprotein protein interactionpublic health prioritiespublic health relevancetrafficking
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Alcohol abuse is a leading factor in mortality from liver disease and increases the risk for a wide range of adverse health effects. The liver, as the primary site of alcohol metabolism, is a major target of injury. The spectrum of Alcoholic Liver Diseases (ALD) includes simple steatosis, alcoholic hepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. Sumoylation is a post-translational modification that modulates multiple cellular processes such as signal transduction, stress responses, cellular trafficking, protein-protein interactions, protein-DNA interactions and transcriptional activity. SUMO is comprised of four distinct proteins in humans (SUMO-1, -2, 3- and -4). Sumoylation is often increased under oxidative stress. We recently reported that ubiquitin conjugating enzyme 9 (Ubc9), the sole E2 enzyme of sumoylation, is induced in intragastric ethanol- infusion (EI) treated mice but the functional significance of this is unknown. Consistently, we found SUMO-1, -3 and Ubc9 mRNA levels are increased the livers of EI mice. Also, EI mice show an overall increase in protein sumoylation by SUMO-1 but only minor changes in sumoylation by SUMO-2/3. Ethanol treatment of primary mouse hepatocytes leads to increased reactive oxygen species (ROS) and triglyceride production. In addition, we found increased expression of Ubc9 and SUMO genes, Cyp2e1 and an overall increase in SUMO-1 protein sumoylation like in EI livers. Silencing of Ubc9 prevented ethanol-induced fat accumulation, ROS production and increased Cyp2e1 expression in primary mouse hepatocytes. In LX-2 cells (activated human hepatic stellate cells or HSCs), ethanol treatment also increased Ubc9 expression, ROS production and HSC activation markers. Blocking Ubc9 induction prevented all of these and induced apoptosis in HSCs. Finally, we found that lipopolysaccharide (LPS) and Ubc9 RNAi treatment alone increased expression of proinflammatory cytokines in RAW cells (macrophage cell line); but when LPS and Ubc9 RNAi were combined, the expression of these cytokines increased further. Interestingly, LPS treatment decreased Ubc9 protein level (mRNA level was unchanged). This proposal is testing the novel hypothesis that there is dysregulation in sumoylation that contributes to the pathogenesis of ALD in a cell-type specific manner. Three specific aims are proposed to examine: 1) the role of sumoylation in ethanol-induced changes in hepatocytes, 2) the role of sumoylation in ethanol-induced HSC activation, and 3) the role of sumoylation in Kupffer cell activation in ALD. If successfully completed, these studies should provide highly novel information on the role of sumoylation in the development of ALD and may provide novel therapeutic strategies, which is of high public health priority.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of StAR-related lipid transfer protein 10 in alcohol-induced breast cancer progression
-
批准号:10734533
-
项目类别:
-
资助金额:$44.95万
-
财政年份:2023
-
负责人:Maria Lauda Tomasi
-
依托单位:
Role of phospho UBC9 in alcohol-associated liver disease
-
批准号:10698107
-
项目类别:
-
资助金额:$44.1万
-
财政年份:2022
-
负责人:Maria Lauda Tomasi
-
依托单位:
A novel biological crosstalk between sumoylation and mitochondria dysfuntion in alcoholic liver disease
-
批准号:10006497
-
项目类别:
-
资助金额:$20.19万
-
财政年份:2019
-
负责人:Maria Lauda Tomasi
-
依托单位:
Role of Sumoylation in Alcoholic Liver Disease
-
批准号:9120737
-
项目类别:
-
资助金额:$16.16万
-
财政年份:2015
-
负责人:Maria Lauda Tomasi
-
依托单位:
Role of Sumoylation in Alcoholic Liver Disease
-
批准号:9320994
-
项目类别:
-
资助金额:$16.16万
-
财政年份:2015
-
负责人:Maria Lauda Tomasi
-
依托单位:
Role of Sumoylation in Alcoholic Liver Disease
-
批准号:8901859
-
项目类别:
-
资助金额:$16.16万
-
财政年份:2015
-
负责人:Maria Lauda Tomasi
-
依托单位:
Role of Sumoylation in Alcoholic Liver Disease
-
批准号:9043309
-
项目类别:
-
资助金额:$15.67万
-
财政年份:2015
-
负责人:Maria Lauda Tomasi
-
依托单位:
Role of SAMe on UBC9 and sumolyation in liver cancer and alcoholic liver injury
-
批准号:8147672
-
项目类别:
-
资助金额:$5.16万
-
财政年份:2010
-
负责人:Maria Lauda Tomasi
-
依托单位:
ROLE OF S-ADENOSYLMETHIONINE ON UBC9 AND SUMOYLATION IN LIVER CANCER AND ALCOHOLI
-
批准号:8061618
-
项目类别:
-
资助金额:$4.79万
-
财政年份:2010
-
负责人:Maria Lauda Tomasi
-
依托单位:
Role of SAMe on UBC9 and sumolyation in liver cancer and alcoholic liver injury
-
批准号:8320778
-
项目类别:
-
资助金额:$5.42万
-
财政年份:2010
-
负责人:Maria Lauda Tomasi
-
依托单位:
海外基金